USA - NASDAQ:PPD - Common Stock
The current stock price of PPD is 47.28 null. In the past month the price increased by 0.06%. In the past year, price increased by 37.36%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.33 | 214.25B | ||
| DHR | DANAHER CORP | 27.94 | 154.22B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.09 | 47.98B | ||
| A | AGILENT TECHNOLOGIES INC | 26.86 | 41.49B | ||
| IQV | IQVIA HOLDINGS INC | 18.61 | 36.80B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.63 | 29.18B | ||
| WAT | WATERS CORP | 28.59 | 20.81B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.9 | 20.28B | ||
| ILMN | ILLUMINA INC | 28.33 | 18.99B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.9 | 16.43B | ||
| TEM | TEMPUS AI INC | N/A | 15.61B | ||
| ICLR | ICON PLC | 13.03 | 13.36B |
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The company is headquartered in Wilmington, North Carolina and currently employs 26,000 full-time employees. The company went IPO on 2020-02-06. The firm provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The firm operates through two segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides a range of services to its customers including early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment provides services to its customers including bioanalytical, vaccine sciences, good manufacturing practice (GMP), central lab and biomarker testing.
PPD Inc
929 North Front Street
Wilmington NORTH CAROLINA 28401 US
CEO: David Simmons
Employees: 26000
Phone: 19102510081.0
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The company is headquartered in Wilmington, North Carolina and currently employs 26,000 full-time employees. The company went IPO on 2020-02-06. The firm provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The firm operates through two segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides a range of services to its customers including early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment provides services to its customers including bioanalytical, vaccine sciences, good manufacturing practice (GMP), central lab and biomarker testing.
The current stock price of PPD is 47.28 null. The price decreased by -0.06% in the last trading session.
PPD does not pay a dividend.
PPD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for PPD Inc (PPD) is 30.31. This is based on the reported non-GAAP earnings per share of 1.56 and the current share price of 47.28 null.
PPD Inc (PPD) has a market capitalization of 17.00B null. This makes PPD a Large Cap stock.
PPD Inc (PPD) will report earnings on 2022-03-01, after the market close.
ChartMill assigns a technical rating of 8 / 10 to PPD. When comparing the yearly performance of all stocks, PPD is one of the better performing stocks in the market, outperforming 82.3% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to PPD. PPD has an average financial health and profitability rating.
Over the last trailing twelve months PPD reported a non-GAAP Earnings per Share(EPS) of 1.56. The EPS increased by 39.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.19% | ||
| ROA | 5.18% | ||
| ROE | N/A | ||
| Debt/Equity | -9.91 |
17 analysts have analysed PPD and the average price target is 48.25 null. This implies a price increase of 2.04% is expected in the next year compared to the current price of 47.28.
For the next year, analysts expect an EPS growth of 37.26% and a revenue growth 31.13% for PPD